- Report
- January 2022
- 40 Pages
Russia
From €2493EUR$2,595USD£2,144GBP
- Report
- January 2022
- 40 Pages
South Korea
From €2493EUR$2,595USD£2,144GBP
- Report
- January 2022
- 40 Pages
United States
From €2493EUR$2,595USD£2,144GBP
- Report
- January 2022
- 40 Pages
Vietnam
From €2493EUR$2,595USD£2,144GBP
- Newsletter
- May 2024
Global
From €1010EUR$1,126USD£899GBP
- Report
- March 2020
- 118 Pages
Global
From €4324EUR$4,500USD£3,718GBP
- Report
- September 2023
- 160 Pages
Global
From €2882EUR$2,999USD£2,478GBP
- Report
- May 2023
- 160 Pages
Global
From €5764EUR$5,999USD£4,956GBP
- Book
- September 2010
- 544 Pages
- Book
- April 2019
- 816 Pages
- Book
- May 2022
- 1040 Pages
- Book
- April 2017
- 232 Pages
- Book
- September 2016
- 680 Pages
- Book
- April 2012
- 1272 Pages
- Book
- April 2010
- 754 Pages
Ulcerative Colitis (UC) is a type of Inflammatory Bowel Disease (IBD) that affects the large intestine. It is characterized by inflammation and ulceration of the inner lining of the colon and rectum. Symptoms of UC include abdominal pain, bloody diarrhea, fatigue, and weight loss. Treatment options for UC include medications, lifestyle changes, and surgery.
The UC market is a subset of the larger Gastroenterology market. It is a growing market, driven by an increasing prevalence of IBD and the development of new treatments. The market is highly competitive, with a number of companies offering treatments for UC.
Some of the companies in the UC market include AbbVie, Allergan, AstraZeneca, Janssen, Pfizer, and Takeda. Show Less Read more
